Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CRDF Cardiff Oncology > Detailed Quotes

CRDF Cardiff Oncology

1.560
+0.020+1.30%
Close 10/03 16:00 ET
1.600
+0.040+2.56%
Post Mkt Price 10/03 17:03 ET
High
1.620
Open
1.620
Turnover
654.66K
Low
1.515
Pre Close
1.540
Volume
422.58K
Market Cap
67.60M
P/E(TTM)
Loss
52wk High
7.320
Shares
43.33M
P/E(Static)
Loss
52wk Low
1.130
Float Cap
62.75M
Bid/Ask %
0.00%
Historical High
81.480
Shs Float
40.22M
Volume Ratio
0.95
Historical Low
0.450
Dividend TTM
--
Div Yield TTM
--
P/B
0.56
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.05%
Amplitude
6.82%
Avg Price
1.549
Lot Size
1
Float Cap
62.75M
Bid/Ask %
0.00%
Historical High
81.480
Shs Float
40.22M
Volume Ratio
0.95
Historical Low
0.450
Dividend TTM
--
P/B
0.56
Dividend LFY
--
Turnover Ratio
1.05%
Amplitude
6.82%
Avg Price
1.549
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
CEO: Dr. Mark Erlander, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...